HIV/AIDS Clinical Trials

Showing 841-860 of 1,802 trials

TDF Long Term Study

NCT01815255

This study will assess the safety and efficacy of generic TDF from Governmental Pharmaceutical Organization (GPO) in HIV-infected children

HIV-infected Thai Children

The HIV Netherlands Australia Thailand Research Collaboration36 participantsStarted Dec 2010

Bangkok, Thailand • Bangkok, Thailand

COMPLETEDPHASE1

This study examines tenofovir (TFV) drug concentrations in adults one day after taking a single dose of Truvada® - a pill used to prevent and treat HIV infection. The results of this study will be used to improve the (efficacy/accuracy) of a white coat adherence (WCA) detection test - a blood test that can be used to indicate medication adherence. Participants will receive one dose of Truvada®, and provide 2 total samples of blood.

Medication AdherenceHIV Prevention

Johns Hopkins University44 participantsStarted Oct 2018

Baltimore, Maryland, United States

COMPLETEDPHASE1

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

NCT03984838

Dolutegravir (DTG), a human immunodeficiency virus (HIV)-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI), are each approved in the United States (US), European Union, and other countries for the treatment of HIV-1 infection. JULUCA is a combination of Dolutegravir and Rilpivirine indicated for the treatment of HIV-1 infection in antiretroviral (ARV) experienced adult subjects who are switching from their current antiretroviral treatment to the 2-drug combination. Although, the pharmacokinetics (PK), safety and tolerability of DTG/RPV (50 milligram \[mg\]/25mg) fixed-dose combination (FDC) tablets have been extensively studied, these parameters have not been assessed exclusively in Japanese subjects. This study will evaluate the pharmacokinetics, safety and tolerability of a single dose DTG/RPV 50 mg/25 mg FDC in a healthy adult Japanese population to support a post-approval commitment for DTG/RPV 50 mg/25 mg FDC in Japan.

HIV Infections

ViiV Healthcare16 participantsStarted Jun 2019

Glendale, California, United States

TDF Long Term Study

Single Dose Truvada Study

Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent

Related Searches

Pregnancy in Women With HIV Infection

MAKASI Intervention for African and Caribbean Migrants' Empowerment in Sexual Health in Paris Greater Area

IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment

Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic

Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM

Genetic Susceptibility to Oncogenic Viruses

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Cryptococcal Antigen Screening Plus Sertraline

Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

MHealth Intervention of HIV and STDs Partner Notification for MSM

Exploring the Comorbidity Between Mental Disorders and General Medical Conditions

Comparative Effectiveness of Brief HIV Care Counseling

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

MISC-CBO in Children Affected by HIV/AIDS

Clinical Characterisation Protocol for COVID-19 in People Living With HIV

Shamba Maisha: Pilot Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya